Predicting neurotoxicity from methotrexate in children with leukemia
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
This study is looking at how certain biological factors might help us understand why some children, especially Latino kids, may experience more side effects from their leukemia treatment with methotrexate, so we can find ways to improve their care and outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11063802 on NIH RePORTER |
What this research studies
This research investigates how certain biological factors can predict the risk of neurotoxicity in children undergoing treatment for acute lymphoblastic leukemia (ALL) with methotrexate. The study focuses on understanding ethnic disparities, particularly among Latino children, who may experience higher rates of treatment-related side effects. By identifying specific host factors that contribute to these toxicities, the research aims to improve treatment outcomes and reduce disparities in survival rates. Patients will be monitored for neurological symptoms that may indicate increased risk, allowing for better management of their treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with acute lymphoblastic leukemia, particularly those from Latino backgrounds.
Not a fit: Patients with other types of leukemia or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols that minimize neurotoxicity and enhance survival rates for children with leukemia.
How similar studies have performed: Previous research has shown that understanding ethnic-specific biological factors can lead to significant improvements in treatment outcomes, suggesting this approach has potential for success.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Brown, Austin L — Baylor College of Medicine
- Study coordinator: Brown, Austin L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.